u/pancreatitis_scare

check who the comparator was before you compare anything

which is exactly what i did in the waiting room, mentally, for about ten minutes.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

nobody mentioned it to me either, and i had read this entire site. it is in the wiki now, which is at least a fixable gap.

The analytical point, which this board keeps getting wrong by importing habits from the peptide side.

For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.

So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.

open-label extensions are not the same evidence as the randomised phase

REDEFINE is the combination programme

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

satiety signalling rather than incretin signalling

How many separate lots has anyone here tested?

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same recepto

Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.

What does the tolerability table in that paper actually say?

long-acting amylin is the whole point of the molecule

Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.

Is that from the publication or the press release?

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

small molecule, not a peptide, and that changes everything about it

Reading the trial literature on this without misleading yourself.

Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.

Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.

Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Absolute or relative risk reduction?

check who the comparator was before you compare anything

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

nothing here is approved as a standalone product and research material is not for human use

Absolute or relative risk reduction?

How to read one of these papers in fifteen minutes, in the order that actually helps.

Start with the registered protocol and check the primary endpoint against what is reported. Then the methods: who was included, what the comparator was, how long the randomised phase ran. Then the discontinuation numbers, which are a tolerability result and are usually in a supplementary table.

Only then the efficacy figure, and read the interval rather than the point estimate. Finish with the limitations section, which is where the authors say what they actually think.

Fifteen minutes, and you will know more than any thread summarising it.

What does the tolerability table in that paper actually say?

amylin and GLP-1 are not redundant pathways

do not assume the dosing intuitions from the GLP-1 boards transfer